Prediction of recurrence with the Oncotype DX recurrence score in node-positive, HR-positive, breast cancer patients treated with adjuvant chemotherapy: Results from PACS01 trial.

被引：4
|
作者：
Penault-Llorca, Frederique Madeleine
Filleron, Thomas
Asselain, Bernard
Baehner, Frederick L.
Fumoleau, Pierre
Lacroix-Triki, Magali
Butler, Steven M.
Jamshidian, Farid
Cherbavaz, Diana B.
Shak, Steven
Roca, Lise
Sagan, Christine
Lemonnier, J.
Martin, Anne-Laure
Roche, Henri Hubert
机构：
[1] Ctr Jean Perrin, Clermont Ferrand, France
[2] Inst Claudius Regaud, Toulouse, France
[3] Curie Site Paris, Paris, France
[4] Genom Hlth Inc, Redwood City, CA USA
[5] Ctr Georges Francois Leclerc, Dijon, France
[6] Inst Reg Canc Montpellier Val dAurelle, Montpellier, France
[7] Inst Cancerol Ouest Site Rene Gauducheau, St Herblain, France
[8] R&D UNICANC, Paris, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.11052
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11052
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Routine Use of Oncotype DX Recurrence Score Testing in Node-Positive Hormone Receptor-Positive HER2-Negative Breast Cancer: The Time Has Come
    Elizabeth A. Mittendorf
    Tari A. King
    Annals of Surgical Oncology, 2019, 26 : 1173 - 1175
  • [32] The recurrence score and chemotherapy treatment in node-positive, ER plus early-stage breast cancer patients in Israel
    Klang, S.
    Liebermann, N.
    Rizel, S.
    Ben-Baruch, N.
    Merling, S.
    Soussan-Gutman, L.
    Bugarini, R.
    Chao, C.
    Shak, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [33] 21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy
    Mamounas, Eleftherios P.
    Liu, Qing
    Paik, Soonmyung
    Baehner, Frederick L.
    Tang, Gong
    Jeong, Jong-Hyeon
    Kim, S. Rim
    Butler, Steven M.
    Jamshidian, Farid
    Cherbavaz, Diana B.
    Sing, Amy P.
    Shak, Steven
    Julian, Thomas B.
    Lembersky, Barry C.
    Wickerham, D. Lawrence
    Costantino, Joseph P.
    Wolmark, Norman
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2017, 109 (04):
  • [34] The 21-Gene Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer Treated on SWOG S8814
    Woodward, W. A.
    Barlow, W. E.
    Jagsi, R.
    Buchholz, T. A.
    Shak, S.
    Baehner, F.
    Yoshizawa, C. N.
    Whelan, T. J.
    Davidson, N. E.
    Ingle, J. N.
    King, T. A.
    Ravdin, P. M.
    Osborne, C. K.
    Tripathy, D.
    Livingston, R. B.
    Gralow, J. R.
    Hortobagyi, G. N.
    Hayes, D. F.
    Albain, K. S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : S146 - S146
  • [35] Reconsidering "at risk" criteria for breast cancer recurrence in hormone positive patients: Risk stratification is still important in patients with an Oncotype Dx recurrence score ≤ 25!
    Turner, B. M.
    Sanders, M. A. G.
    Soukiazian, A.
    Soukiazian, N.
    Hicks, D. G.
    CANCER RESEARCH, 2019, 79 (04)
  • [36] The Effect of Oncotype Dx® Recurrence Score on Treatment Recommendations for Patients with Early Stage Estrogen Receptor Positive Breast Cancer
    Acs, G.
    Esposito, N.
    Kiluk, J.
    Laronga, C.
    Lee, M. C.
    Loftus, L.
    Soliman, H.
    Boughey, J. C.
    Reynolds, C.
    Acs, P.
    Gordan, L.
    CANCER RESEARCH, 2009, 69 (24) : 726S - 726S
  • [37] Survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer patients in a randomised trial.
    Kummel, S.
    Krocker, J.
    Kohls, A.
    Breitbach, G-P
    Budner, M.
    Keil, E.
    Hinke, A.
    Blohmer, J-U
    Elling, D.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S113 - S113
  • [38] Breast cancer specific survival in 38,568 patients with node negative hormone receptor positive invasive breast cancer and oncotype DX recurrence score results in the SEER database
    Shak, S.
    Petkov, V. I.
    Miller, D. P.
    Howlader, N.
    Gliner, N.
    Howe, W.
    Schussler, N.
    Cronin, K.
    Baehner, F. L.
    Penberthy, L.
    CANCER RESEARCH, 2016, 76
  • [39] An optimized Breast Cancer Index node-positive (BCIN plus ) prognostic model for late distant recurrence in patients with hormone receptor-positive (HR plus ) node-positive breast cancer
    Liefers, G-J.
    Noordhoek, I.
    Zhang, Y.
    Sgroi, D. C.
    Putter, H.
    Treuner, K.
    Wong, J.
    Kranenbarg, E. Meershoek-Klein
    Duijm-De Carpentier, M.
    van de Velde, C.
    Schnabel, C. A.
    ANNALS OF ONCOLOGY, 2021, 32 : S23 - S24
  • [40] Combination of predicted sensitivity to endocrine therapy (SET2,3 index) and the Recurrence Score in node-positive breast cancer: Independent validation in the PACS-01 trial
    Penault-Llorca, Frederique Madeleine
    Lusque, Amelie
    Filleron, Thomas
    Tran, Kevin
    Du, Lili
    Baehner, Frederick
    Dalenc, Florence
    Lacroix-Triki, Magali
    Bachelot, Thomas
    Andre, Fabrice
    Boucher, Pascal
    Lemonnier, Jerome
    Symmans, W. Fraser Fraser
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345